{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:04:36Z","timestamp":1790467476447,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bulcan.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T12:49:00Z","timestamp":1542890940000},"page":"1202-1208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Donn\u00e9es d\u2019efficacit\u00e9 et de toxicit\u00e9 des immunoth\u00e9rapies anti canc\u00e9reuses chez le sujet \u00e2g\u00e9\u00a0\u2013\u00a05e journ\u00e9e de pharmacologie des anti-tumoraux"],"prefix":"10.1016","volume":"105","author":[{"given":"Hortense","family":"Gaultier De Saint Basile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Poisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Boudou-Rouquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00e9onore","family":"De Guillebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bulcan.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.bulcan.2018.10.004_bib0125","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0135","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2018.10.004_bib0145","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer","volume":"9","author":"Yamashita","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bulcan.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2\u00a0study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0155","unstructured":"Les cancers en France, Les Donn\u00e9es, INCa, \u00e9dition 2015."},{"key":"10.1016\/j.bulcan.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/eji.201546178","article-title":"Aging of the immune system: focus on inflammation and vaccination","volume":"46","author":"Pinti","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgo.2017.02.001","article-title":"Immunotherapy comes of age: immune aging & checkpoint inhibitors","volume":"8","author":"Elias","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri2471","article-title":"The ageing immune system: is it ever too old to become young again?","volume":"9","author":"Dorshkind","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10064","key":"10.1016\/j.bulcan.2018.10.004_bib0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2\u00a0trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0200","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1200\/JCO.2016.34.15_suppl.3070","article-title":"Is there a clinical benefit of anti-PD-1\u00a0in patients older than 75\u00a0years with previously treated solid tumour?","volume":"34","author":"Landre","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"6\u20137","key":"10.1016\/j.bulcan.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1051\/medsci\/20183406007","article-title":"Is it possible to use immune checkpoint inhibitors in patients with autoimmune or inflammatory disease?","volume":"34","author":"Danlos","year":"2018","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-9966-33-30","article-title":"Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme","volume":"33","author":"Chiarion Sileni","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1200\/JCO.2016.34.15_suppl.10010","article-title":"FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers","volume":"34","author":"Singh","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T19:49:53Z","timestamp":1605469793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118303102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0007455118303102"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.10.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donn\u00e9es d\u2019efficacit\u00e9 et de toxicit\u00e9 des immunoth\u00e9rapies anti canc\u00e9reuses chez le sujet \u00e2g\u00e9\u00a0\u2013\u00a05e journ\u00e9e de pharmacologie des anti-tumoraux","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}